苯酮尿症治療市場－全球產業規模、佔有率、趨勢、機會和預測：按給藥途徑、產品、分銷管道、地區和競爭對手分類，2021-2031年

全球苯酮尿症治療市場預計將從 2025 年的 5.8104 億美元成長到 2031 年的 9.5373 億美元，複合年成長率為 8.61%。

此領域涵蓋針對先天性苯丙胺酸代謝紊亂的專門醫學營養和藥物療法。推動這一領域發展的關鍵因素包括新生兒篩檢計畫的普及，這些計畫能夠實現早期發現，以及旨在開發新型酵素替代療法和基因療法的強力的研究舉措。此外，患者權益倡導組織透過動員社區參與研究，在加速臨床進展方面發揮至關重要的作用。例如，美國國家苯酮尿症聯盟報告稱，到2025年，其苯酮尿症患者登記系統已獲得來自36個國家的1125名參與者的同意，有助於收集對治療方法創新至關重要的真實世界數據。

儘管取得了這些進展，但市場成長在長期堅持嚴格的飲食和用藥方案方面仍面臨許多挑戰。終身管理帶來的嚴重生活方式限制和心理社會挑戰往往導致藥物依從性低下，尤其是在成年人中。這種依從性不足不僅降低了治療產品的實際商業性需求，也使新藥臨床療效的檢驗變得更加複雜，因為不穩定的患者參與會阻礙研發進程。

市場促進因素

基因療法和新一代生物製藥的引入正在徹底改變全球苯酮尿症治療市場，使治療標準從溫和的飲食限制轉向根治性或疾病改善治療方法。製藥公司正致力於將針對潛在酵素缺陷的創新藥物商業化，從而減少患者對嚴格合成飲食的依賴。這項轉變因突破性的監管進展而更加凸顯。例如，美國食品藥物管理局(FDA) 已核准其產品 Sephience 中的 sepiapterin 用於成人和兒童患者，PTC Therapeutics 公司宣布該藥物將於 2025 年 7 月獲批。此類核准凸顯了先進小分子化合物的臨床潛力，促進了市場競爭，並擴大了非飲食療法的可及性。

同時，對罕見疾病研發投入的增加正在擴大在研藥物的管線。孤兒藥認定等支持性監管機制為此提供了保障。生物技術公司正積極資助早期臨床試驗，以滿足苯丙胺酸氧化酵素穩定劑和基因編輯領域尚未滿足的需求。例如，Agios Pharmaceuticals公司於2025年1月報告稱，其針對苯酮尿症設計的新型穩定劑AG-181已成功應用於首例I期臨床試驗患者。這些投資正在豐富治療方法，並保持現有領導企業的商業性發展勢頭。例如，BioMarin Pharmaceuticals公司報告稱，其酵素替代療法藥物Palingic在2025年的季度銷售額達到1.09億美元。

市場挑戰

確保患者長期堅持嚴格的飲食和藥物治療仍然是苯酮尿症治療行業商業性發展的主要障礙。這種依從性差的問題，尤其是在成人患者中更為突出，顯著縮小了有效特製醫學食品和療法的市場。當患者因飲食疲勞或嚴重的心理社會壓力而放棄治療時，現有產品的持續收入會受到影響，開發新的終身治療方法的經濟可行性也會受到質疑。此外，高依從率會阻礙臨床試驗，不一致的數據會掩蓋臨床實驗藥物的療效，導致監管核准延誤，並增加研發者的風險。

這種脫落模式顯著減少了已確診人口的消費群。根據美國國家苯酮尿症協會2025年的數據，受訪的成年患者中有25.5%完全停止了飲食療法，只有43.8%嚴格遵守了治療方案。這些數據凸顯了治療流程中存在嚴重的脫落問題，顯示儘管有多種治療選擇，但仍有相當一部分患者退出了市場。因此，由於理論患者數量並不能可靠地反映長期治療性介入的患者數量，製造商難以準確預測投資報酬率。

市場趨勢

開發偏好、以患者為中心的特殊醫學用途食品，旨在透過改善蛋白質替代品的口味和營養價值，解決長期飲食依從性難題。製造商正利用先進的加工技術生產基於Glico(GMP) 的配方，以掩蓋合成氨基酸的苦味並減少攝取。這一趨勢透過提供更便利的日常選擇，直接緩解了青少年和成年人的飲食疲勞問題。例如，2025 年 12 月，Arla Foods Ingredients 宣布推出 Lacprodan CGMP-30，這是苯丙胺酸含量比傳統產品低 50% 的成分。這將有助於生產在顯著降低蛋白質攝取量的同時維持代謝控制的特殊醫學用途食品。

除了營養方面的改善，人們越來越傾向於選擇能夠幫助患者放寬飲食限制的治療方法，這推動了能夠放寬飲食限制的藥物干預措施迅速進入市場。與傳統的症狀治療不同，現代口服藥物能夠增強苯丙胺酸耐受性，並使患者能夠重新攝取天然蛋白質。這種向生活​​方式支持治療方法的轉變已迅速取得了商業性成功，表明偏好對能夠減輕疾病帶來的社會心理負擔的解決方案有著強烈的需求。例如，PTC Therapeutics公司在2025年11月報告稱，其新推出的Sepiapterin療法在上市後的前兩個月就實現了1,960萬美元的淨銷售額。這凸顯了市場對真正能夠帶來飲食自由的治療方法的強勁需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：苯酮尿症治療的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 給藥途徑（口服、注射）
  • 依產品類型（營養補充品、藥品）
  • 分銷管道（醫院藥局、網路藥局、小兒科診所）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美苯酮尿症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲苯酮尿症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區苯乙酮尿症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲苯酮尿症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美苯酮尿症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球苯酮尿症治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• BioMarin Pharmaceutical Inc.
• Synlogic, Inc.
• Retrophin, Inc.
• Daiichi Sankyo Company, Limited
• Codexis, Inc.
• SOM Innovation Biotech SL
• Homology Medicines, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Phenylketonuria Treatment Market is projected to expand from USD 581.04 Million in 2025 to USD 953.73 Million by 2031, reflecting a compound annual growth rate of 8.61%. This sector encompasses specialized medical nutrition and pharmacological treatments aimed at managing the congenital inability to metabolize phenylalanine. Key factors fueling this growth include the widespread adoption of newborn screening programs, which ensure early detection, alongside robust research initiatives dedicated to developing novel enzyme substitution and gene therapies. Furthermore, patient advocacy groups play a pivotal role in accelerating clinical progress by mobilizing communities for research; for example, the National PKU Alliance reported that by 2025, their PKU Patient Registry had consented 1,125 participants across 36 countries, facilitating the gathering of real-world data essential for therapeutic innovation.

Despite these advancements, market growth faces a significant hurdle regarding the long-term maintenance of strict dietary and medication regimens. The profound lifestyle restrictions and psychosocial challenges associated with lifelong management frequently lead to poor compliance, especially within the adult demographic. This lack of adherence not only diminishes the actual commercial demand for therapeutic products but also creates complexities in clinically validating new agents, as inconsistent patient participation hampers the development process.

Market Driver

The introduction of gene therapies and next-generation biologics is revolutionizing the Global Phenylketonuria Treatment Market, moving the standard of care from palliative dietary restrictions toward curative or disease-altering solutions. Pharmaceutical companies are focusing on commercializing innovative pharmacological agents that target root enzymatic deficits, thereby reducing patient reliance on rigorous synthetic diets. This shift is highlighted by regulatory milestones such as the U.S. Food and Drug Administration's approval of sepiapterin for both adult and pediatric populations, as announced by PTC Therapeutics, Inc. in July 2025 regarding their product 'Sephience.' Such approvals confirm the clinical potential of advanced small molecules, stimulating competition and expanding access to non-dietary treatments.

Simultaneously, increased investment in research and development for rare diseases is expanding the pipeline of investigational drugs, bolstered by supportive regulatory mechanisms like orphan drug designations. Biotechnology companies are actively funding early-stage trials to address unmet needs in phenylalanine hydroxylase stabilization and gene editing. For instance, Agios Pharmaceuticals, Inc. reported in January 2025 that it had successfully dosed the first participants in a Phase 1 study for AG-181, a novel stabilizer designed for phenylketonuria. This financial commitment diversifies available therapies and maintains commercial momentum for established leaders, evidenced by BioMarin Pharmaceutical Inc. reporting $109 million in quarterly revenue for its enzyme substitution therapy Palynziq in 2025.

Market Challenge

The ongoing struggle to secure long-term patient adherence to strict dietary and pharmacological protocols remains a major obstacle to the commercial growth of the phenylketonuria treatment industry. This compliance deficit, which is especially pronounced among adults, significantly shrinks the effective market for specialized medical foods and therapeutics. When patients abandon treatment due to diet fatigue or severe psychosocial pressures, the recurring revenue for existing products suffers, casting doubt on the financial viability of developing new lifelong therapies. Moreover, high non-compliance rates interfere with clinical trials, as inconsistent data can mask the efficacy of investigational drugs, causing expensive delays in regulatory approvals and heightening risk for developers.

This pattern of attrition notably depletes the consumer base within the diagnosed community. Data from the National Society for Phenylketonuria in 2025 indicated that a survey of adult patients found 25.5% had entirely stopped their dietary treatment, while only 43.8% adhered strictly to their regimen. These figures highlight a critical leakage in the treatment funnel, where a substantial portion of the population exits the market despite available options. Consequently, manufacturers struggle to accurately forecast return on investment, as the theoretical patient count does not reliably translate into a consistent volume of long-term users for therapeutic interventions.

Market Trends

The development of palatable and patient-centric medical food formulations is tackling the issue of long-term dietary adherence by enhancing the taste and nutritional efficiency of protein substitutes. Manufacturers are leveraging advanced processing techniques to produce glycomacropeptide (GMP)-based formulas that mask the bitterness of synthetic amino acids and reduce the volume required for consumption. This trend directly addresses diet fatigue in adolescents and adults by providing options that fit better into everyday life. For example, in December 2025, Arla Foods Ingredients introduced Lacprodan CGMP-30, an ingredient containing 50% less phenylalanine than previous iterations, facilitating the production of medical foods that maintain metabolic control with a significantly reduced protein load.

Alongside these nutritional improvements, the market is seeing rapid adoption of pharmaceutical interventions designed to liberalize diets, as patients prioritize therapies that allow for relaxed dietary constraints. In contrast to earlier palliative treatments, modern oral agents are positioned to increase phenylalanine tolerance, enabling the reintroduction of natural protein. This move toward lifestyle-enabling treatments has gained immediate commercial success, proving the high demand for solutions that alleviate the condition's psychosocial burden. As evidence of this preference, PTC Therapeutics reported in November 2025 that their newly launched sepiapterin therapy achieved $19.6 million in net product revenue within its first two months, highlighting the market's strong desire for interventions that offer genuine dietary freedom.

Key Market Players

• BioMarin Pharmaceutical Inc.
• Synlogic, Inc.
• Retrophin, Inc.
• Daiichi Sankyo Company, Limited
• Codexis, Inc.
• SOM Innovation Biotech SL
• Homology Medicines, Inc.

Report Scope

In this report, the Global Phenylketonuria Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Phenylketonuria Treatment Market, By Route of Administration

• Oral
• Parenteral

Phenylketonuria Treatment Market, By Product

• Dietary Supplement
• Drugs

Phenylketonuria Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Pediatric Clinics

Phenylketonuria Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Phenylketonuria Treatment Market.

Available Customizations:

Global Phenylketonuria Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Phenylketonuria Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Oral, Parenteral)
  • 5.2.2. By Product (Dietary Supplement, Drugs)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Pediatric Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Phenylketonuria Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Product
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Phenylketonuria Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Phenylketonuria Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Phenylketonuria Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Distribution Channel

7. Europe Phenylketonuria Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Product
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Phenylketonuria Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Phenylketonuria Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Phenylketonuria Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Phenylketonuria Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Phenylketonuria Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Phenylketonuria Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Product
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Phenylketonuria Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Phenylketonuria Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Phenylketonuria Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Phenylketonuria Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Phenylketonuria Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Phenylketonuria Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Product
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Phenylketonuria Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Phenylketonuria Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Phenylketonuria Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Distribution Channel

10. South America Phenylketonuria Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Product
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Phenylketonuria Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Phenylketonuria Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Phenylketonuria Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Phenylketonuria Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. BioMarin Pharmaceutical Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Synlogic, Inc.
• 15.3. Retrophin, Inc.
• 15.4. Daiichi Sankyo Company, Limited
• 15.5. Codexis, Inc.
• 15.6. SOM Innovation Biotech SL
• 15.7. Homology Medicines, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer